Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Relapsed T-Cell Acute Lymphoblastic Leukemia Clinical Trial

Official title: A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC

Status Terminated

Clinical Trial Summary

Nelarabine has shown significant activity in patients with T-cell malignancies. This study will determine the safety and maximum tolerated dose of the combination of nelarabine, cyclophosphamide and etoposide in patients with first bone marrow relapse of T-ALL, or first relapse of T-LL.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
• Relapsed T-Cell Acute Lymphoblastic Leukemia
• Relapsed T-Cell Lymphoblastic Lymphoma

• NCT number: NCT00981799
• Study type: Interventional
• Source: Therapeutic Advances in Childhood Leukemia Consortium
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: June 2010
• Completion date: July 18, 2016